BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 24 /PRNewswire-FirstCall/ -- Shire Pharmaceuticals Group plc will announce third quarter 2005 US GAAP earnings on Thursday, November 3, 2005.
Results announcement time: 12:00 GMT / 07:00 ET Conference call time: 14:00 GMT / 09:00 ET Live conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call at 14:00 GMT/09:00 ET.
Please RSVP ssalah@uk.shire.com (T: +44-(0)1256-894-160). The details of the live conference call are as follows: UK dial in +44-(0)-1452-568-061 US / Canada dial in 1866-224-2972 Password Shire Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations/Events section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows:
UK dial in 0845-245-5205 US dial in 18662474222 Stnd Int Dial In Number +44-(0)-1452-55-00-00 Pin code 1684507 # Webcast Replay www.shire.com, in the investor relations section
If you have any problems accessing this, please contact: Souheil Salah on: +44-(0)-1256-894160
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetic therapies. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company's website: www.shire.com.
Shire Pharmaceuticals Group PlcCONTACT: For further information please contact: Investor Relations,Souheil Salah (Rest of the World), +44-1256-894-160; Heidi Wunder (NorthAmerica), +1-484-595-8709
